BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer

To Investigate the Prevalence of BRCA 1/2 Mutation Among Ovarian Cancer Clinical Trial

Official title: Prevalence Study of Germline and/or Somatic BRCA1/2 Mutation in Korean Patients With High-Grade Serous and/or Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status Completed

Clinical Trial Summary

PURPOSE: To investigate the prevalence and clinical correlation of the germline BRCA 1/2 mutation in Korean patients with high grade(HG) serous and/or endometrioid epithelial ovarian cancer (EOC).

PATIENTS AND METHODS: In a nationwide case-control study on EOC conducted in Korea between 2010 and 2015, 298 Korean women with HG serous and/or endometrioid EOC were tested for gBRCA 1/2 mutation, regardless of the family history. Mutation screening was performed using the Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) and Ion PGM platform according to the manufacturer's instructions. Clinical characteristics including survival outcome was assessed in gBRCAm carriers.

Clinical Trial Description

n/a

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Ovarian Neoplasms
• To Investigate the Prevalence of BRCA 1/2 Mutation Among Ovarian Cancer

• NCT number: NCT02963688
• Study type: Observational
• Source: Samsung Medical Center
• Status: Completed
• Phase: N/A
• Start date: January 2010
• Completion date: December 2015